Angiogenesis is the process of the formation of new blood vessels from those that already exist. Angiogenesis is an important function in the oxygenation of tissues, and can help in various functions including wound healing and the treatment of vascular diseases such as heart disease, high blood pressure, and diabetes. An abnormal rate of angiogenesis, however, can cause many problems including the proliferation of cancerous tumors, diabetic ulcers, and cardiovascular diseases. Many scientists have studied factors of angiogenesis such as macrophages, and treatments have been created that work in the negative regulation of angiogenesis, including sphingosine-1 phosphate and TCF8. Consequently, researchers are also looking to inhibit proteins that facilitate angiogenesis, such as VEGF. There also exist factors that work on the positive regulation of angiogenesis, such as the hypoxia-inducible factor, that allows for blood vessels to grow and further distribute oxygen throughout a body suffering from hypoxia.
Regulation Of Angiogenesis Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Regulation Of Angiogenesis below!
For more information on how to use Laverne, please read the How to Guide.
We have 2948 products for the study of the Regulation Of Angiogenesis Pathway that can be applied to Chromatin Immunoprecipitation, Western Blot, Immunocytochemistry/Immunofluorescence, Flow Cytometry, Chromatin Immunoprecipitation (ChIP), Immunohistochemistry from our catalog of antibodies and ELISA kits.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.